Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects

Journal of Pharmacology and Experimental Therapeutics

Volumn 353, Issue 1, 2015, Pages 102-111

  Schmid, Yasmin ^a   Rickli, Anna ^a   Schaffner, Antonia ^a   Duthaler, Urs ^a   Grouzmann, Eric ^b   Hysek, Cédric M ^a   Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADRENALIN; AMFEBUTAMONE; DOPAMINE; HYDROCORTISONE; NORADRENALIN; OXYTOCIN; PLACEBO; PROLACTIN; DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; PSYCHOTROPIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BRUXISM; CONCENTRATION LOSS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LOSS OF APPETITE; MALE; MAXIMUM PLASMA CONCENTRATION; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; XEROSTOMIA; YOUNG ADULT; BLOOD; DRUG EFFECTS; DRUG INTERACTION; METABOLISM;

ADULT; BUPROPION; CROSS-OVER STUDIES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; EPINEPHRINE; FEMALE; HEART RATE; HUMANS; HYDROCORTISONE; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; OXYTOCIN; PROLACTIN; PSYCHOTROPIC DRUGS; YOUNG ADULT;

EID: 84928936463     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.222356     Document Type: Article

References (55)

1. Andersen PH (1989) The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166:493-504.
2. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, and Martin BR (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66:675-682.
3. de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, and Farre M (2012) MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Front Genet 3:235.
4. Dunand M, Gubian D, Stauffer M, Abid K, and Grouzmann E (2013) Highthroughput and sensitive quantitation of plasma catecholamines by ultraperformance liquid chromatography-tandem mass spectrometry using a solid phase microwell extraction plate. Anal Chem 85:3539-3544.
5. Eisenhofer G, Rundquist B, Aneman A, Friberg P, Dakak N, Kopin IJ, Jacobs MC, and Lenders JW (1995) Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 80: 3009-3017.
6. Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, Chiang N, Kahn R, Vocci F, Ling W, et al. (2008) Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 33:1162-1170.
7. Esler M, Jennings G, Lambert G, Meredith I, Horne M, and Eisenhofer G (1990) Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 70:963-985.
8. Farré M, Abanades S, Roset PN, Peiró AM, Torrens M, O'Mathúna B, Segura M, and de la Torre R (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323:954-962.
9. Goldstein DS and Holmes C (2008) Neuronal source of plasma dopamine. Clin Chem 54:1864-1871.
10. Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, and Gasior M (2009) The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep 32:1425-1438.
11. Heal DJ, Gosden J, and Smith SL (2014) Dopamine reuptake transporter (DAT) "inverse agonism"-a novel hypothesis to explain the enigmatic pharmacology of cocaine. Neuropharmacology 87:19-40.
12. Heinzerling KG, Swanson AN, Hall TM, Yi Y, Wu Y, and Shoptaw SJ (2014) Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction 109: 1878-1886.
13. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28: 1176-1183.
14. Hicks JK, Swen JJ, Thom CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Müller DJ, Gaedigk A, and Stingl JC; Clinical Pharmacogenetics Implementation Consortium (2013) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93:402-408.
15. Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, Hoener MC, and Liechti ME (2012a) Effects of the α2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4- methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340:286-294.
16. Hysek CM, Domes G, and Liechti ME (2012b) MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. Psychopharmacology (Berl) 222:293-302.
17. Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, and Liechti ME (2013) a-Adrenergic receptors contribute to the acute effects of 3,4-methtlenedioxymethamphetamine in humans. J Clin Psychopharmacol 33:658-666.
18. Hysek CM and Liechti ME (2012) Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology (Berl) 224:363-376.
19. Hysek C, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, and Liechti ME (2012c) Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol 166:2277-2288.
20. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, and Liechti ME (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects ofMDMA ("ecstasy") in humans. Clin Pharmacol Ther 90:246-255.
21. Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, Huwyler J, Hoener MC, and Liechti ME (2012d) Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebocontrolled laboratory study. PLoS ONE 7:e36476.
22. Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, Grouzmann E, and Liechti ME (2014) Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol 17:371-381.
23. Jefferson JW, Pradko JF, and Muir KT (2005) Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 27:1685-1695.
24. Kharasch ED, Mitchell D, and Coles R (2008) Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol 48:464-474.
25. Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, and Adson DE (2005) Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 25: 226-229.
26. Kreth K, Kovar K, Schwab M, and Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 59:1563-1571.
27. Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, and Langstrom B (2003) In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 54: 800-805.
28. Liechti ME, Baumann C, Gamma A, and Vollenweider FX (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22: 513-521.
29. Liechti ME and Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14: 269-274.
30. Mori T, Uzawa N, Kazawa H, Watanabe H, Mochizuki A, Shibasaki M, Yoshizawa K, Higashiyama K, and Suzuki T (2014) Differential substitution for the discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and methylphenidate in rats. J Pharmacol Exp Ther 350:403-411.
31. Neumann ID, Maloumby R, Beiderbeck DI, Lukas M, and Landgraf R (2013) Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology 38:1985-1993.
32. Newton TF, Roache JD, De La Garza R, 2nd, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, and Kahn R (2005) Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl) 182: 426-435.
33. Newton TF, Roache JD, De La Garza R, 2nd, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, and Kahn R (2006) Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 31: 1537-1544.
34. Oliveto A, McCance-Katz FE, Singha A, Petrakis I, Hameedi F, and Kosten TR (2001) Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug Alcohol Depend 63:155-167.
35. Peck AW and Hamilton M (1983) Psychopharmacology of bupropion in normal volunteers. J Clin Psychiatry 44:202-205.
36. Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, and McConn DJ (2008) An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 36:1198-1201.
37. Reichel CM, Murray JE, Grant KM, and Bevins RA (2009) Bupropion attenuates methamphetamine self-administration in adult male rats. Drug Alcohol Depend 100:54-62.
38. Richelson E and Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104: 277-286.
39. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, and Geyer MA (2006) Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31: 2349-2358.
40. Schindler CW, Gilman JP, Panlilio LV, McCann DJ, and Goldberg SR (2011) Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys. Exp Clin Psychopharmacol 19:1-10.
41. Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, and Liechti ME (2014) Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol 28:847-856.
42. Segura M, Farré M, Pichini S, Peiró AM, Roset PN, Ramírez A, Ortuño J, Pacifici R, Zuccaro P, Segura J, et al. (2005) Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 44:649-660.
43. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, and Liechti ME (2013a) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458-470.
44. Simmler LD, Rickli A, Schramm Y, Hoener MC, and Liechti ME (2014) Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem Pharmacol 88:237-244.
45. Simmler LD, Wandeler R, and Liechti ME (2013b) Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence (Abstract). BMC Res Notes 6: 220.
46. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, and Learned-Coughlin S (2004) A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 6: 159-166.
47. Steuer AE, Schmidhauser C, Liechti ME, and Kraemer T (2014) Development and validation of an LC-MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma. Drug Test Anal 10.1002/ dta.1740.
48. Tancer M and Johanson CE (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 189:565-573.
49. Trojan A, Vergopoulos A, Breitenstein U, Seifert B, Rageth C, and Joechle W (2012) The discrimiminatory value of CYP2D6 genotyping in predicting the dextromethorphan/dextrorphan phenotype in women with breast cancer. Breast Care (Basel) 7:25-31.
50. Verrico CD, Lynch L, Fahey MA, Fryer AK, Miller GM, and Madras BK (2008) MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor. J Psychopharmacol 22:187-202.
51. Verrico CD, Miller GM, and Madras BK (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189: 489-503.
52. White TL, Justice AJ, and de Wit H (2002) Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73:729-741.
53. Wise RA (2008) Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res 14:169-183.
54. Zerssen DV (1976) Die Beschwerden-Liste, Münchener Informationssystem. Psychis, Munich, Germany.
55. Zhu AZX, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, and Tyndale RF (2012) CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther 92:771-777.